Global AI Drug Discovery Software 麻豆原创 Research Report 2024

Publication ID:

PB511240171

Publication Date:

November 14, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

The global AI Drug Discovery Software market was valued at US$ 470 million in 2023 and is anticipated to reach US$ 1119 million by 2030, witnessing a CAGR of 14.0% during the forecast period 2024-2030.
AI drug discovery software is a software tool that accelerates the drug development process by utilizing artificial intelligence algorithms and technologies. This software integrates and analyzes a vast amount of bioinformatics data, chemical structure data, and clinical trial data to predict key properties such as compound bioactivity, pharmacokinetic characteristics, and toxicity. With the help of AI technology, drug researchers can more quickly and accurately screen potential candidate drugs, thereby reducing development costs, shortening development cycles, and improving success rates.
North American market for AI Drug Discovery Software is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for AI Drug Discovery Software is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for AI Drug Discovery Software in CRO and Universities is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of AI Drug Discovery Software include Nanolive, TandemAI, Benevolent, Atomwise, Cradle, Exscientia, Iktos, Insilico Medicine, Collaborative Drug Discovery, Valence Labs, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for AI Drug Discovery Software, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AI Drug Discovery Software.
The AI Drug Discovery Software market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global AI Drug Discovery Software market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the AI Drug Discovery Software companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Nanolive
TandemAI
Benevolent
Atomwise
Cradle
Exscientia
Iktos
Insilico Medicine
Collaborative Drug Discovery
Valence Labs
Certara
Insilico
Genentech
Merck
Segment by Type
Cloud Based
On Premise
Segment by Application
CRO and Universities
Pharmaceutical Company
Test Lab
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of AI Drug Discovery Software company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global AI Drug Discovery Software 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Cloud Based
1.2.3 On Premise
1.3 麻豆原创 by Application
1.3.1 Global AI Drug Discovery Software 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 CRO and Universities
1.3.3 Pharmaceutical Company
1.3.4 Test Lab
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global AI Drug Discovery Software 麻豆原创 Perspective (2019-2030)
2.2 Global AI Drug Discovery Software Growth Trends by Region
2.2.1 Global AI Drug Discovery Software 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 AI Drug Discovery Software Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 AI Drug Discovery Software Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 AI Drug Discovery Software 麻豆原创 Dynamics
2.3.1 AI Drug Discovery Software Industry Trends
2.3.2 AI Drug Discovery Software 麻豆原创 Drivers
2.3.3 AI Drug Discovery Software 麻豆原创 Challenges
2.3.4 AI Drug Discovery Software 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top AI Drug Discovery Software Players by Revenue
3.1.1 Global Top AI Drug Discovery Software Players by Revenue (2019-2024)
3.1.2 Global AI Drug Discovery Software Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global AI Drug Discovery Software 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by AI Drug Discovery Software Revenue
3.4 Global AI Drug Discovery Software 麻豆原创 Concentration Ratio
3.4.1 Global AI Drug Discovery Software 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by AI Drug Discovery Software Revenue in 2023
3.5 Global Key Players of AI Drug Discovery Software Head office and Area Served
3.6 Global Key Players of AI Drug Discovery Software, Product and Application
3.7 Global Key Players of AI Drug Discovery Software, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 AI Drug Discovery Software Breakdown Data by Type
4.1 Global AI Drug Discovery Software Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global AI Drug Discovery Software Forecasted 麻豆原创 Size by Type (2025-2030)
5 AI Drug Discovery Software Breakdown Data by Application
5.1 Global AI Drug Discovery Software Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global AI Drug Discovery Software Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America AI Drug Discovery Software 麻豆原创 Size (2019-2030)
6.2 North America AI Drug Discovery Software 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America AI Drug Discovery Software 麻豆原创 Size by Country (2019-2024)
6.4 North America AI Drug Discovery Software 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe AI Drug Discovery Software 麻豆原创 Size (2019-2030)
7.2 Europe AI Drug Discovery Software 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe AI Drug Discovery Software 麻豆原创 Size by Country (2019-2024)
7.4 Europe AI Drug Discovery Software 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific AI Drug Discovery Software 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific AI Drug Discovery Software 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific AI Drug Discovery Software 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific AI Drug Discovery Software 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America AI Drug Discovery Software 麻豆原创 Size (2019-2030)
9.2 Latin America AI Drug Discovery Software 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America AI Drug Discovery Software 麻豆原创 Size by Country (2019-2024)
9.4 Latin America AI Drug Discovery Software 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa AI Drug Discovery Software 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa AI Drug Discovery Software 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa AI Drug Discovery Software 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa AI Drug Discovery Software 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Nanolive
11.1.1 Nanolive Company Details
11.1.2 Nanolive Business Overview
11.1.3 Nanolive AI Drug Discovery Software Introduction
11.1.4 Nanolive Revenue in AI Drug Discovery Software Business (2019-2024)
11.1.5 Nanolive Recent Development
11.2 TandemAI
11.2.1 TandemAI Company Details
11.2.2 TandemAI Business Overview
11.2.3 TandemAI AI Drug Discovery Software Introduction
11.2.4 TandemAI Revenue in AI Drug Discovery Software Business (2019-2024)
11.2.5 TandemAI Recent Development
11.3 Benevolent
11.3.1 Benevolent Company Details
11.3.2 Benevolent Business Overview
11.3.3 Benevolent AI Drug Discovery Software Introduction
11.3.4 Benevolent Revenue in AI Drug Discovery Software Business (2019-2024)
11.3.5 Benevolent Recent Development
11.4 Atomwise
11.4.1 Atomwise Company Details
11.4.2 Atomwise Business Overview
11.4.3 Atomwise AI Drug Discovery Software Introduction
11.4.4 Atomwise Revenue in AI Drug Discovery Software Business (2019-2024)
11.4.5 Atomwise Recent Development
11.5 Cradle
11.5.1 Cradle Company Details
11.5.2 Cradle Business Overview
11.5.3 Cradle AI Drug Discovery Software Introduction
11.5.4 Cradle Revenue in AI Drug Discovery Software Business (2019-2024)
11.5.5 Cradle Recent Development
11.6 Exscientia
11.6.1 Exscientia Company Details
11.6.2 Exscientia Business Overview
11.6.3 Exscientia AI Drug Discovery Software Introduction
11.6.4 Exscientia Revenue in AI Drug Discovery Software Business (2019-2024)
11.6.5 Exscientia Recent Development
11.7 Iktos
11.7.1 Iktos Company Details
11.7.2 Iktos Business Overview
11.7.3 Iktos AI Drug Discovery Software Introduction
11.7.4 Iktos Revenue in AI Drug Discovery Software Business (2019-2024)
11.7.5 Iktos Recent Development
11.8 Insilico Medicine
11.8.1 Insilico Medicine Company Details
11.8.2 Insilico Medicine Business Overview
11.8.3 Insilico Medicine AI Drug Discovery Software Introduction
11.8.4 Insilico Medicine Revenue in AI Drug Discovery Software Business (2019-2024)
11.8.5 Insilico Medicine Recent Development
11.9 Collaborative Drug Discovery
11.9.1 Collaborative Drug Discovery Company Details
11.9.2 Collaborative Drug Discovery Business Overview
11.9.3 Collaborative Drug Discovery AI Drug Discovery Software Introduction
11.9.4 Collaborative Drug Discovery Revenue in AI Drug Discovery Software Business (2019-2024)
11.9.5 Collaborative Drug Discovery Recent Development
11.10 Valence Labs
11.10.1 Valence Labs Company Details
11.10.2 Valence Labs Business Overview
11.10.3 Valence Labs AI Drug Discovery Software Introduction
11.10.4 Valence Labs Revenue in AI Drug Discovery Software Business (2019-2024)
11.10.5 Valence Labs Recent Development
11.11 Certara
11.11.1 Certara Company Details
11.11.2 Certara Business Overview
11.11.3 Certara AI Drug Discovery Software Introduction
11.11.4 Certara Revenue in AI Drug Discovery Software Business (2019-2024)
11.11.5 Certara Recent Development
11.12 Insilico
11.12.1 Insilico Company Details
11.12.2 Insilico Business Overview
11.12.3 Insilico AI Drug Discovery Software Introduction
11.12.4 Insilico Revenue in AI Drug Discovery Software Business (2019-2024)
11.12.5 Insilico Recent Development
11.13 Genentech
11.13.1 Genentech Company Details
11.13.2 Genentech Business Overview
11.13.3 Genentech AI Drug Discovery Software Introduction
11.13.4 Genentech Revenue in AI Drug Discovery Software Business (2019-2024)
11.13.5 Genentech Recent Development
11.14 Merck
11.14.1 Merck Company Details
11.14.2 Merck Business Overview
11.14.3 Merck AI Drug Discovery Software Introduction
11.14.4 Merck Revenue in AI Drug Discovery Software Business (2019-2024)
11.14.5 Merck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Nanolive
TandemAI
Benevolent
Atomwise
Cradle
Exscientia
Iktos
Insilico Medicine
Collaborative Drug Discovery
Valence Labs
Certara
Insilico
Genentech
Merck

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.